Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02450539
Registration number
NCT02450539
Ethics application status
Date submitted
19/05/2015
Date registered
21/05/2015
Date last updated
13/08/2021
Titles & IDs
Public title
A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer
Query!
Scientific title
A Randomized Phase 2 Study of Abemaciclib (LY2835219) Versus Docetaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
Query!
Secondary ID [1]
0
0
I3Y-MC-JPBX
Query!
Secondary ID [2]
0
0
15806
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Non-Small Cell Lung Cancer Stage IV
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Lung - Mesothelioma
Query!
Cancer
0
0
0
0
Query!
Lung - Non small cell
Query!
Cancer
0
0
0
0
Query!
Lung - Small cell
Query!
Intervention/exposure
Study type
Interventional(has expanded access)
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Abemaciclib
Treatment: Drugs - Docetaxel
Experimental: Abemaciclib - 200 milligram (mg) abemaciclib given orally every 12 hours (Q12H) on days 1 to 21 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
Active Comparator: Docetaxel - 75 milligram per meter squared (mg/m²) docetaxel given intravenously (IV) on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
Treatment: Drugs: Abemaciclib
Administered orally
Treatment: Drugs: Docetaxel
Administered IV
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Progression Free Survival (PFS)
Query!
Assessment method [1]
0
0
PFS was defined as time from the date of randomization to the date of investigator-determined disease progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1) or death from any cause. Progressive disease (PD) was defined as at least a 20% increase in the sum of the longest diameters (LD) of target lesions, with reference the smallest sum on study and an absolute increase of at least 5mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant was not known to have died or have objective progression, PFS time will be censored at the day of their last radiographic tumor assessment (if available) or date of randomization if no post baseline radiographic assessment is available.
Query!
Timepoint [1]
0
0
Baseline to Objective Progression or Death from Any Cause ( Up To 6 Months)
Query!
Secondary outcome [1]
0
0
Pharmacokinetics (PK): Clearance of Abemaciclib
Query!
Assessment method [1]
0
0
Pharmacokinetics (PK): Clearance of Abemaciclib
Query!
Timepoint [1]
0
0
Cycle (C) 1 Day (D) 1: Pre-dose; C1D8: 4 and 7 hr Post-dose; C2D1: Pre-dose and 3 hr Post-dose; C3 and C4 D1:Pre-dose
Query!
Secondary outcome [2]
0
0
PK: Volume of Distribution of Abemaciclib
Query!
Assessment method [2]
0
0
PK: Volume of Distribution of Abemaciclib
Query!
Timepoint [2]
0
0
Cycle (C) 1 Day (D) 1: Pre-dose; C1D8: 4 and 7 hr Post-dose; C2D1: Pre-dose and 3 hr Post-dose; C3 and C4 D1:Pre-dose
Query!
Secondary outcome [3]
0
0
Overall Survival (OS)
Query!
Assessment method [3]
0
0
OS was defined as the time from randomization to the date of death due to any cause. For each participant who is not known to have died as the data inclusion cutoff date for overall survival analysis, OS time was censored on the last date the participant is known to be alive.
Query!
Timepoint [3]
0
0
Baseline to Date of Death from Any Cause (Up To 28 Months)
Query!
Secondary outcome [4]
0
0
Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR])
Query!
Assessment method [4]
0
0
Overall response was defined as the percentage of randomized participants achieving a best overall response (BoR) of complete response (CR) or partial response (PR) using Response Evaluation Criteria In Solid Tumors (RECIST v1.1) criteria. Participants with unevaluable or unknown response status are considered nonresponders. Complete response (CR) is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. Partial response (PR) is defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions and no appearance of new lesions.
Query!
Timepoint [4]
0
0
Baseline to Objective Progression (Up To 6 Months)
Query!
Secondary outcome [5]
0
0
Percentage of Participants Who Exhibit Stable Disease (SD) or Confirmed Response (CR) or Partial Response (PR): Disease Control Rate (DCR)
Query!
Assessment method [5]
0
0
DCR is the percentage of randomized participants who achieved a complete response, partial response or stable disease using Response Evaluation Criteria In Solid Tumors (RECIST v1.1) criteria. Complete response (CR) is defined as the disappearance of all target and non-target lesions, and no appearance of new lesions. Partial response (PR) is defined as at least a 30% decrease in the sum of longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions and no appearance of new lesions. Stable disease was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions.
Query!
Timepoint [5]
0
0
Baseline through Measured Progressive Disease or Death Due to Any Cause (Up To 6 Months)
Query!
Secondary outcome [6]
0
0
Time to Worsening of Eastern Cooperative Oncology Group (ECOG) Performance Status of >/=2
Query!
Assessment method [6]
0
0
Worsening of ECOG performance status is the duration from randomization to ECOG PFS of >/=2. Participants without an ECOG PFS >/=2 are censored at last adequate post baseline ECOG Performance Status or randomization date (whichever is last).
The ECOG Performance Status:0 - Fully active, able to carry on all pre-disease performance without restriction,1 - Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, 2 - Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours,3 - Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours, 4 - Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair, 5 - Dead
Query!
Timepoint [6]
0
0
Randomization to ECOG PFS of >/=2 (Up To 11.5 Months)
Query!
Secondary outcome [7]
0
0
Change From Baseline in MD Anderson Symptom Inventory-Lung Cancer (MDASI-LC) Scores
Query!
Assessment method [7]
0
0
MDASI-LC included 33 items:6 interference and 27 symptom(3 lung-cancer (LC),8 brain tumor (BT),and 3 study-specific(headache,diarrhea, and rash).Analyzed endpoints were 9 constructs:3 single-items (headache,diarrhea,and rash) and 6 composites(interference+core,LC,core+LC,BT, and core+LC worst 5 baseline).Data for all 9 constructs were collected by an 11-point numeric rating scale anchored at 0(not present or does not interfere) and 10(as bad as you can imagine or interfered completely).The measurement range was 10 (maximum score-minimum score). Between-group difference in regression-predicted change from baseline were estimated for each specified construct. MMRM models included independent variables treatment,visit, treatment*visit,and baseline score. Group-level negative change from baseline indicated group improvement.
Query!
Timepoint [7]
0
0
Baseline through End of Study (Up To 6 Months)
Query!
Secondary outcome [8]
0
0
Change From Baseline in EuroQol 5-Dimensional 5-Level (EQ-5D-5L) Questionnaire EQ VAS Overall Self-rated Health Score
Query!
Assessment method [8]
0
0
The EQ-5D-5L is a standardized instrument for use as a measure of self-reported health status. Overall self-rated health was measured with a vertical 20 cm visual analog scale (VAS) anchored at 0 (worst health) and ranged through 100 (best health). Between-group differences in regression-predicted change from baseline score were estimated for VAS scores. MMRM models included independent variables treatment, visit, treatment*visit, and baseline score. Group-level negative change from baseline indicated group improvement.
Query!
Timepoint [8]
0
0
Baseline to Measured Progressive Disease (Up To 6 Months)
Query!
Secondary outcome [9]
0
0
Change From Baseline in EuroQol 5-Dimensional 5-Level (EQ-5D-5L) Questionnaire Index Value
Query!
Assessment method [9]
0
0
There are 5 response levels on a good-to-bad continuum of 1-5 corresponding to none, slight, moderate, severe, and extreme/unable to.The EuroQol-developed crosswalk method was used to convert the EQ-5D-5L,using UK weights,health dimensions(mobility,self-care,usual activities,pain/discomfort, and anxiety/depression) into a single index value;the dimensions are not separately scored.The index is marked missing when =1 dimensions are missing.The index scores for the response patterns were anchored on full health to dead with negative values assigned to response patterns/health states considered worse than death.The best pattern is assigned the index value of 1.0; the worst pattern is assigned an index value of -0.594. Between-group differences in regression-predicted change from baseline score were estimated for the index .MMRM models included independent variables treatment, visit, treatment*visit, and baseline score.Group-level negative change from baseline indicated group improvement.
Query!
Timepoint [9]
0
0
Baseline to Measured Progressive Disease (Up To 6 Months)
Query!
Eligibility
Key inclusion criteria
- Confirmed diagnosis of stage IV NSCLC.
- Have progressed during or after platinum-based chemotherapy for advanced disease.
- Have not received prior treatment with docetaxel.
- Have availability of adequate formalin-fixed paraffin-embedded (FFPE) tumor derived
material.
- Have adequate organ function including hematology, renal, and liver.
- Have good performance score (0-1).
- Have measurable disease per RECIST 1.1.
- Agree to use a reliable medically approved method of birth control.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Have received prior treatment with any cyclin dependent kinase (CDK) 4 and 6 inhibitor
or participated in a clinical trial with a CDK 4 and 6 inhibitor and the treatment
administered is not known.
- Are currently receiving treatment in a clinical trial involving an investigational
product or non-approved use of a drug or device.
- Have the presence of unstable central nervous system (CNS) metastasis.
- Have had major surgery (excluding biopsy) < 28 days of the initial dose of study drug.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
6/08/2015
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
29/07/2020
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
159
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Camperdown
Query!
Recruitment hospital [2]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Randwick
Query!
Recruitment hospital [3]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - South Brisbane
Query!
Recruitment hospital [4]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Wollongong
Query!
Recruitment hospital [5]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Woolloongabba
Query!
Recruitment postcode(s) [1]
0
0
2050 - Camperdown
Query!
Recruitment postcode(s) [2]
0
0
2013 - Randwick
Query!
Recruitment postcode(s) [3]
0
0
4101 - South Brisbane
Query!
Recruitment postcode(s) [4]
0
0
2500 - Wollongong
Query!
Recruitment postcode(s) [5]
0
0
4102 - Woolloongabba
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arkansas
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Kansas
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Missouri
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
New York
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Washington
Query!
Country [6]
0
0
France
Query!
State/province [6]
0
0
Paris
Query!
Country [7]
0
0
France
Query!
State/province [7]
0
0
Strasbourg
Query!
Country [8]
0
0
France
Query!
State/province [8]
0
0
Suresnes
Query!
Country [9]
0
0
Germany
Query!
State/province [9]
0
0
Berlin
Query!
Country [10]
0
0
Germany
Query!
State/province [10]
0
0
Gera
Query!
Country [11]
0
0
Germany
Query!
State/province [11]
0
0
Halle
Query!
Country [12]
0
0
Germany
Query!
State/province [12]
0
0
Heidelberg
Query!
Country [13]
0
0
Germany
Query!
State/province [13]
0
0
Koln
Query!
Country [14]
0
0
Hungary
Query!
State/province [14]
0
0
Budapest
Query!
Country [15]
0
0
Hungary
Query!
State/province [15]
0
0
Gyor
Query!
Country [16]
0
0
Italy
Query!
State/province [16]
0
0
Bari
Query!
Country [17]
0
0
Italy
Query!
State/province [17]
0
0
Firenze
Query!
Country [18]
0
0
Italy
Query!
State/province [18]
0
0
Monza
Query!
Country [19]
0
0
Italy
Query!
State/province [19]
0
0
Torino
Query!
Country [20]
0
0
Korea, Republic of
Query!
State/province [20]
0
0
Cheongju
Query!
Country [21]
0
0
Korea, Republic of
Query!
State/province [21]
0
0
Seoul
Query!
Country [22]
0
0
Korea, Republic of
Query!
State/province [22]
0
0
Ulsan-si
Query!
Country [23]
0
0
Poland
Query!
State/province [23]
0
0
Krakow
Query!
Country [24]
0
0
Poland
Query!
State/province [24]
0
0
Lodz
Query!
Country [25]
0
0
Poland
Query!
State/province [25]
0
0
Olsztyn
Query!
Country [26]
0
0
Poland
Query!
State/province [26]
0
0
Poznan
Query!
Country [27]
0
0
Poland
Query!
State/province [27]
0
0
Warszawa
Query!
Country [28]
0
0
Romania
Query!
State/province [28]
0
0
Baia Mare
Query!
Country [29]
0
0
Romania
Query!
State/province [29]
0
0
Cluj-Napoca
Query!
Country [30]
0
0
Romania
Query!
State/province [30]
0
0
Craiova
Query!
Country [31]
0
0
Russian Federation
Query!
State/province [31]
0
0
St Petersburg
Query!
Country [32]
0
0
Russian Federation
Query!
State/province [32]
0
0
Volzhsky
Query!
Country [33]
0
0
Spain
Query!
State/province [33]
0
0
Barcelona
Query!
Country [34]
0
0
Spain
Query!
State/province [34]
0
0
Madrid
Query!
Country [35]
0
0
Spain
Query!
State/province [35]
0
0
Pamplona
Query!
Country [36]
0
0
Spain
Query!
State/province [36]
0
0
Sevilla
Query!
Country [37]
0
0
Taiwan
Query!
State/province [37]
0
0
Taichung
Query!
Country [38]
0
0
Taiwan
Query!
State/province [38]
0
0
Tainan
Query!
Country [39]
0
0
Taiwan
Query!
State/province [39]
0
0
Taipei
Query!
Country [40]
0
0
Ukraine
Query!
State/province [40]
0
0
Dnipropetrovsk
Query!
Country [41]
0
0
Ukraine
Query!
State/province [41]
0
0
Kharkiv
Query!
Country [42]
0
0
Ukraine
Query!
State/province [42]
0
0
Kriviy Rig
Query!
Country [43]
0
0
Ukraine
Query!
State/province [43]
0
0
Vinnitsa
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Eli Lilly and Company
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The main purpose of this study is to evaluate the effectiveness of the study drug known as
abemaciclib versus docetaxel in participants with stage IV squamous non-small cell lung
cancer (NSCLC) previously treated with platinum-based chemotherapy.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02450539
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Query!
Address
0
0
Eli Lilly and Company
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02450539
Download to PDF